Corcept Therapeutics
CORT
199 hedge funds and large institutions have $1.77B invested in Corcept Therapeutics in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 70 increasing their positions, 75 reducing their positions, and 26 closing their positions.
36% more call options, than puts
Call options by funds: $11.7M | Put options by funds: $8.59M
0.53% less ownership
Funds ownership: 69.59% → 69.05% (-0.53%)
7% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 75
5% less funds holding
Funds holding: 209 → 199 (-10)
9% less capital invested
Capital invested by funds: $1.94B → $1.77B (-$171M)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$16.4M |
| 2 |
EIP
Epoch Investment Partners
New York
|
+$12.4M |
| 3 |
JP Morgan Chase
New York
|
+$10.4M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$2.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$12.3M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$9.15M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.13M |
| 4 |
AWS
AJ Wealth Strategies
New York
|
-$6.02M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$5.8M |
CORT Hedge Fund Activity: Q2 2021 in Review
199 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2021, worth a combined $1.77B — down 8.8% from $1.94B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CORT and 16 opened new positions — a net loss of 10 holders — while 75 trimmed existing stakes and 70 added.
The largest buyer was TD Asset Management, adding an estimated $16.4M. The largest seller was BlackRock, cutting an estimated $12.3M.
- 199 institutional investors held Corcept Therapeutics (CORT) as of Q2 2021, down from 209 in Q1 2021.
- Funds reported $1.77B of Corcept Therapeutics stock for Q2 2021, down 8.8% quarter-over-quarter.
- 16 funds opened new Corcept Therapeutics positions in Q2 2021 and 26 closed out, a net change of -10 holders.
- The largest Corcept Therapeutics buyer in Q2 2021 was TD Asset Management, an estimated $16.4M added.
- The largest Corcept Therapeutics seller in Q2 2021 was BlackRock, an estimated $12.3M sold.
Based on aggregated 13F filings for Q2 2021.